Type a ticker — we pressure-test it against live facts, filings, and sentiment.
Beam Therapeutics Inc. — Healthcare · Biotechnology carries a Plainview business-quality score of 5.6/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.
On the fundamentals, Beam Therapeutics Inc. shows trailing revenue of $164.0M, net cash of $1.11B, a loss per share of -4.05, valued at about 21.5x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.